Search
Colorado Paid Clinical Trials
A listing of 1810 clinical trials in Colorado actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1285 - 1296 of 1810
Colorado is currently home to 1810 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Psilocybin Therapy in Advanced Cancer
Recruiting
The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of meaning and hope; fear of death) in advanced cancer (i.e., stage 3 or 4). Study medications will be administered in conjunction with brief psychotherapy that is designed to treat anxiety, depression and existential distress in advanced cancer.
Gender:
ALL
Ages:
Between 21 years and 100 years
Trial Updated:
01/14/2025
Locations: University of Colorado Anschutz Medical campus (CU AMC), Aurora, Colorado
Conditions: Advanced Cancer
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Recruiting
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
Gender:
ALL
Ages:
Between 29 days and 21 years
Trial Updated:
01/14/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Acute Myeloid Leukemia
GORE® ENFORM Biomaterial Product Study
Recruiting
A prospective, retrospective, non-randomized, multicenter study with two independent hernia study cohorts (Ventral / Incisional Hernia Repair and Diaphragmatic / Hiatal Hernia Repair). The primary objective of this study is to collect GORE® ENFORM Biomaterial product commercial-use data on device functional performance and short-term patient experience.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Institute of Esophageal and Reflux Surgery, Denver, Colorado
Conditions: Hernia, Hiatal, Hernia, Diaphragmatic, Hernia, Ventral, Incisional Hernia
Von Willebrand Factor in Pregnancy (VIP) Study
Recruiting
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding.
This is a prospective, open-label, cohort study in women with VWD using Wilate VWF replacement therapy to maintain trough or minimum VWF levels of 100-150% for delivery and the immediate postpartum peri... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: University of Colorado, Aurora, Colorado
Conditions: Von Willebrand Diseases
Lynch Syndrome Integrative Epidemiology and Genetics
Recruiting
The vision of the "Lynch syndrome INtegrative Epidemiology And GEnetics" (LINEAGE) Consortium is to collaboratively improve the lives and longevity of individuals and families with Lynch syndrome.
The mission of the LINEAGE Consortium is to collaboratively improve Lynch syndrome care through high-quality research. This consortium will provide intellectual and infrastructure support to facilitate development of research questions, collection of standardized data and biospecimens, support of gran... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: University of Colorado, Aurora, Colorado
Conditions: Lynch Syndrome
Spine Procedures Assisted with RoboTics and Navigation
Recruiting
Creation of a pediatric robotic spine surgery registry will allow for data collection and analysis on the coupled use of robotics and navigation, as well as patient-specific rods in pediatric spine deformity surgery across participating study institutions. Eventually, an educational and informative framework for this technology will be established.
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
01/13/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Spine Deformity, Idiopathic Scoliosis, Adolescent Idiopathic Scoliosis, Spondylolisthesis, Congenital Scoliosis, Neuromuscular Scoliosis
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
Recruiting
This protocol pertains specifically to the prospective lung squamous cell carcinoma pre-malignant lesion (PML) cohort that will form a primary study group for the Lung Pre-Cancer Atlas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: Rocky Mountain Regional VAMC, Aurora, Colorado
Conditions: Lung Cancer
The Healthy Families Bright Futures Program
Recruiting
The goal of this clinical trial is to learn about an online group program (Healthy Families Bright Futures program) for LGBTQ+ teens and their caregivers. The main question\[s\] it aims to answer are: • is this program acceptable, appropriate, and feasible for LGBTQ+ youth and their caregivers • does the program affect teen (alcohol use, dating violence, alcohol use refusal self-efficacy, healthy communication self-efficacy) and caregiver (accepting behaviors, parenting self-efficacy, parenting... Read More
Gender:
ALL
Ages:
Between 15 years and 18 years
Trial Updated:
01/10/2025
Locations: University of Colorado Colorado Springs, Colorado Springs, Colorado
Conditions: Alcohol Drinking, Violence in Adolescence
Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Recruiting
There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal symptom burden and treatment tolerability utilizing validated patient-reported outcomes (PROs) instruments.
Primary Objective:
* To develop the data collection infrastructure required to prospectively collect longitudinal electronic patient-reported outcomes (PROs) survey instruments in adult and pe... Read More
Gender:
ALL
Ages:
8 years and above
Trial Updated:
01/10/2025
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as assessed by ORR, PFS and OS after prior treatment with a taxane, trastuzumab, and T-DM1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: University of Colorado, Aurora, Colorado
Conditions: Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
ALL
Ages:
All
Trial Updated:
01/10/2025
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Breast Cancer
Adipocyte-Derived Extracellular Vesicles, Weight Loss, and Endothelial Function
Recruiting
Changes in adipose tissue biology are now recognized as a key factor underlying the increased risk of metabolic and cardiovascular disease with obesity. Clinical interest in adipocyte-derived extracellular vesicles (Ad-EVs) has intensified due to their potential as circulating biomarkers of adipose tissue health and systemic messengers, regulators and mediators of cardiometabolic health and disease with obesity.
The investigators hypothesize that elevated Ad-EVs in adults with obesity will be n... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
01/09/2025
Locations: University of Colorado Boulder Clinical and Translational Research Center (CTRC), Boulder, Colorado
Conditions: Obesity, Weight Loss